SIRT2 and metabolic dysfunction-associated steatotic liver disease: Generally, lysophosphatidylcholine (LPC) and phosphatidylcholines (PC), downregulated in SIRT2 KO mice and enriched in the hepatoprotective choline metabolism and glycerophospholipid metabolism pathways, inhibit the progression of NAFLD via lipotropic action and alleviating hypercholesterolemia [19,20,21].